Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft synthesis: Completeness of certificates of analysis in… — submissions

The 8 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-105/2
Series
Public comment period
Version
1.0
Published
12 Dec 2025
Last reviewed
12 Dec 2025
Next review
12 Dec 2026
Identifier
10.71829/cei.cp.105
Certainty
Not rated
Cycle
2025 Q4
Window
06 Oct 2025 – 03 Nov 2025
Status
Closed
Submissions
8

§2Submissions and responses

8 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Jerome Petrossian, PhD (Chemistry), MRSC University department of pharmacy practice
DRAFT-COA-COMPLETE/007 received 08 Oct 2025

A funnel plot is presented for a set too small to interpret it

The draft includes a funnel plot for an outcome contributed by fewer than ten studies. The respondent states that asymmetry cannot be assessed reliably at that number and that presenting the plot invites a conclusion the data cannot support.

The respondent proposes that the plot be removed and replaced with a statement that publication bias could not be assessed.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseAccepted13 Nov 2025

The secretariat accepts this submission. Presenting an uninterpretable graphic is not a neutral act.

The funnel plot is removed for every outcome contributed by fewer than ten studies, and replaced by a statement that small-study effects could not be assessed at that number, together with the count of registered trials identified without posted results.

Dr Theodora Ximenes, PhD (Pharmaceutics) Endocrine surgery service · industry submission
DRAFT-COA-COMPLETE/008 received 08 Oct 2025

A sponsor trial meeting the eligibility criteria was excluded

The submission is made on behalf of the sponsor. It identifies a completed trial of the sponsor's compound that meets the stated eligibility criteria and does not appear in the included set, and supplies the trial report and the registry record.

The sponsor asks that the trial be included and the estimate recomputed. No view is expressed on the direction the recomputation should take.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseAccepted in part04 Dec 2025

The secretariat accepts this submission in part. The trial does meet the criteria and has been included. The recomputed estimate is materially unchanged, which the response states explicitly so that the outcome of the correction is on the record.

The trial is added to the included set, the estimate and the certainty rating have been recomputed, and the screening record now states why the trial was missed, which was a database indexing gap rather than a screening judgement. The submission is identified as an industry submission.

Dr Quintus Kettlewell, PharmD, MSc National medicines information service
DRAFT-COA-COMPLETE/005 received 14 Oct 2025

The document is unreadable without specialist training

The respondent, a trustee of a patient organisation, states that the draft is written for a reader who already understands certainty grading, and that the people most affected by the subject matter will not reach the assessment at all.

The respondent proposes a plain-language summary at the head of every document, written to the same standard of accuracy as the document itself and not as a promotional abstract.

Declared interest. Holds a patent relating to a delivery technology referenced in the draft.
Secretariat responseAccepted in part13 Nov 2025

The secretariat accepts this submission in part. A plain-language summary is added. The proposal that it replace the technical abstract is declined, because the abstract is the part of the document other assessors read and cite.

Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.

Dr Theodora Ingelbrecht, MSc, CChem Academic sports-medicine and anti-doping laboratory
DRAFT-COA-COMPLETE/006 received 18 Oct 2025

Baseline imbalance in a small contributing trial is not remarked on

The respondent identifies a small contributing trial with a baseline difference in the outcome variable, and states that the difference is large enough to account for a share of the reported effect.

The respondent asks that the trial be excluded or that the imbalance be addressed.

Declared interest. Is a trustee of a patient organisation that has received a restricted educational grant from a manufacturer in the class under assessment.
Secretariat responseNoted, no amendment27 Nov 2025

The secretariat notes this submission. The imbalance is recorded in the risk-of-bias assessment for that trial, in the domain concerning the randomisation process, where the respondent may not have looked.

No amendment arises. The judgement and the supporting figures are already reported at domain level for that study, and a sensitivity analysis omitting it is reported in the results, which does not change the direction of the estimate.

Dr Ottoline Oppenheimer-Ade, MD, MPH Primary-care research network
DRAFT-COA-COMPLETE/004 received 22 Oct 2025

The review protocol is described but its registration record is not linked

The respondent asks for the prospective registration record of the review protocol so that the registered outcomes can be compared with the reported ones.

The respondent states that without it the claim of prospective registration cannot be checked.

Declared interest. Employed by a national competent authority. This submission is made in a personal capacity and does not represent the position of that authority.
Secretariat responseAccepted in part28 Nov 2025

The secretariat accepts this submission in part. The protocol is published in full on the Institute site with its version history, which permits the comparison the respondent asks for. Where an external registration identifier is not held by the Institute, the review says so rather than supplying one.

Each synthesis now links its own protocol with the version in force at screening, and states explicitly where an external registration identifier is not held, so that the absence is a recorded fact.

Dr Hortensia Larsson-Ekwueme, MSc (Regulatory Affairs) Public-sector clinical trials unit
DRAFT-COA-COMPLETE/003 received 24 Oct 2025

Analytical surveys are treated as evidence about suppliers when they establish only what was in a sample

Several included surveys purchased material anonymously and analysed it. The respondent states that where the chain from a named supplier to the analysed vial cannot be documented, the result describes a sample and not a supplier.

The respondent proposes that provenance be an explicit eligibility dimension, with surveys reported separately according to whether it could be established.

Declared interest. No financial interest. Has published a systematic review reaching a different conclusion from the draft, which the respondent declares as a non-financial interest.
Secretariat responseAccepted27 Nov 2025

The secretariat accepts this submission. Moderate certainty evidence from the included surveys supports statements about material circulating in a market; it does not support statements about any named supplier's output.

Provenance is now assessed for every included survey and reported as a study characteristic, surveys without establishable provenance are reported separately rather than pooled with those that have it, and no supplier-level inference is drawn from a sample-level result.

Dr Quentin Whitmarsh-Obi, MD, FRCS Academic peptide-chemistry group
DRAFT-COA-COMPLETE/002 received 30 Oct 2025

Risk-of-bias judgements are reported as an overall rating without the domains

The draft reports a single overall risk-of-bias judgement per study. The respondent states that the overall judgement conceals which domain drove it, and that a reader assessing whether the concern applies to their question needs the domain.

The respondent proposes a domain-level table with the supporting quotation for each judgement.

Declared interest. No interest to declare. The respondent is a graduate student and states that the submission forms no part of any assessed work.
Secretariat responseAccepted04 Dec 2025

The secretariat accepts this submission. The overall judgement is a summary of the domains and publishing only the summary makes it uncheckable.

Risk of bias is now reported at domain level for every included study, with the text on which each judgement was based quoted and referenced, and the overall judgement derived from the domains rather than asserted alongside them.

Dr Delphine Trelawney, MSc (Regulatory Affairs) Public-sector clinical trials unit
DRAFT-COA-COMPLETE/001 received 03 Nov 2025

The review does not say when it will be updated or what would trigger an update

The respondent states that a synthesis in a field where trials report frequently is out of date from the day it is published, and that a reader has no way to know whether the version in front of them is current.

The respondent proposes a stated trigger for an update as well as a scheduled review date.

Declared interest. Employed by a health technology assessment body that has issued guidance on a compound named in the draft.
Secretariat responseAccepted20 Nov 2025

The secretariat accepts this submission. A review date alone tells a reader when the document will be looked at, not whether it should already have been.

Every synthesis now records a scheduled review date and a stated update trigger, being the reporting of a trial that would materially change the contributing evidence, and the registered trials capable of triggering an update are listed by name.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.